128 related articles for article (PubMed ID: 38876762)
1. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.
Silke F; Earl L; Hsu J; Janko MM; Joffe J; Memetova A; Michael D; Zheng P; Aravkin A; Murray CJL; Weaver MR
Lancet Glob Health; 2024 Jul; 12(7):e1159-e1173. PubMed ID: 38876762
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis.
Rosettie KL; Joffe JN; Sparks GW; Aravkin A; Chen S; Compton K; Ewald SB; Mathew EB; Michael D; Pedroza Velandia P; Miller-Petrie MB; Stafford L; Zheng P; Weaver MR; Murray CJL
PLoS One; 2021; 16(12):e0260808. PubMed ID: 34928971
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
[TBL] [Abstract][Full Text] [Related]
5. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study.
Rodriguez PJ; Roberts DA; Meisner J; Sharma M; Owiredu MN; Gomez B; Mello MB; Bobrik A; Vodianyk A; Storey A; Githuka G; Chidarikire T; Barnabas R; Barr-Dichiara M; Jamil MS; Baggaley R; Johnson C; Taylor MM; Drake AL
Lancet Glob Health; 2021 Jan; 9(1):e61-e71. PubMed ID: 33227254
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
[TBL] [Abstract][Full Text] [Related]
8. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
9. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators
Lancet; 2024 May; 403(10440):2133-2161. PubMed ID: 38642570
[TBL] [Abstract][Full Text] [Related]
10. Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.
Cirera L; Galatas B; Alonso S; Paaijmans K; Mamuquele M; Martí-Soler H; Guinovart C; Munguambe H; Luis F; Nhantumbo H; Montañà J; Bassat Q; Candrinho B; Rabinovich R; Macete E; Aide P; Alonso P; Saúte F; Sicuri E
PLoS One; 2020; 15(7):e0235631. PubMed ID: 32628741
[TBL] [Abstract][Full Text] [Related]
11. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Diseases and Injuries Collaborators
Lancet; 2020 Oct; 396(10258):1204-1222. PubMed ID: 33069326
[TBL] [Abstract][Full Text] [Related]
12. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Causes of Death Collaborators
Lancet; 2024 May; 403(10440):2100-2132. PubMed ID: 38582094
[TBL] [Abstract][Full Text] [Related]
13. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
14. Optimizing HIV retesting during pregnancy and postpartum in four countries: a cost-effectiveness analysis.
Meisner J; Roberts DA; Rodriguez P; Sharma M; Newman Owiredu M; Gomez B; de Mello MB; Bobrik A; Vodianyk A; Storey A; Githuka G; Chidarikire T; Barnabas R; Farid S; Essajee S; Jamil MS; Baggaley R; Johnson C; Drake AL
J Int AIDS Soc; 2021 Apr; 24(4):e25686. PubMed ID: 33787064
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
[TBL] [Abstract][Full Text] [Related]
16. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
GBD 2016 DALYs and HALE Collaborators
Lancet; 2017 Sep; 390(10100):1260-1344. PubMed ID: 28919118
[TBL] [Abstract][Full Text] [Related]
17. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.
Seo MK; Baker P; Ngo KN
Malar J; 2014 Feb; 13():66. PubMed ID: 24564883
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
